Phase 2 Study Comparing TL-925 Eye Drops to Placebo for Treating Seasonal Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model

What this Trial Is About

Researchers are evaluating TL-925, an eye drop formulation, for its potential to treat seasonal allergic conjunctivitis using the conjunctival allergen challenge model. This Phase 2, randomized, double-masked, vehicle-controlled study aims to assess the safety and efficacy of TL-925 compared to a placebo in adults with documented ocular allergies. The study is sponsored by Telios Pharma, Inc. and involves about 60 eligible participants. Participants will be randomly assigned in equal numbers to receive either TL-925 or a placebo eye drop. Both treatments will be administered bilaterally as topical ophthalmic eye drops in a clinical setting. The study includes a screening phase followed by a treatment period where the allergic conjunctivitis response will be evaluated using controlled allergen exposure. Throughout the study, participants will be dosed in the clinic, and researchers will monitor ocular itching and conjunctival redness at specific time points after allergen challenge. The primary outcomes focus on itching measured at 3, 5, and 7 minutes and redness at 7, 15, and 20 minutes post-challenge. The total participation duration is aligned with the screening and treatment phases ending by February 2026, with careful safety and efficacy assessments conducted during this time.

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis